CLKpicture.jpg
 

Cecilia Kronawitter

President
HDA Enterprises, Inc.

Cecilia Kronawitter is experienced in designing, developing, managing and marketing healthcare facilities. She has achieved a strong track record and made valuable contacts throughout all facets of the healthcare community.

Cecilia began her career as a facility planner and quickly rose to department head of a well-known architectural firm, specializing in healthcare. From there, she decided to open her own firm, where she has personally directed the development of more than 200 facilities worldwide. Each of these facilities continues to operate today.

In addition, she corporately or personally participates in the American Society of Ophthalmic Administrators (ASOA), the Ambulatory Surgery Center Association, APIC, ASORN, AORN, ASCA and SGNA. She’s also a published author with many articles about improving healthcare practices.

In 2007, Cecilia opened a sister company to HDA Enterprises (HDAE), where she collaborated with innovative management professionals and formed HDA International Management, LLC, a company offering a full range of healthcare management consulting services. Since then, Cecilia has also led her team in mastering the implementations and integrations of Paperless Electronic Health Records Systems. She has successfully integrated several clients nationwide to paperless facilities, as well as integrated their electronic health records systems to work in unison via interfaces with both their billing and scheduling software and with practices, hospitals and other healthcare organizations.

Cecilia also founded and continues to spearhead the Foundation for Healthcare for Humanity (FHH), the humanitarian arm of HDAE. Cecilia remains active in efforts to provide healthcare in third world countries and rural areas of the United States through FHH.

As president, Cecilia continues to bring new and innovative alternatives to meet the ever-changing challenges the healthcare industry brings to our clients and the healthcare market overall.